AnalystBook Research · Company Intelligence

Bowhead Specialty Holdings Inc.

BOWNYSE

Built from Bowhead Specialty Holdings Inc.'s own SEC filings · updates as new filings land · sources cited throughout

or browse all covered companies

Bowhead Specialty grew FY2025 revenue 29.6% and net income 40.6% across specialty P&C lines, while new debt and insider sales add caution.

The read at a glance✓ Audited against SEC data
  • Business mixSpecialty P&C insuranceNote
  • Revenue$551.6M, +29.6%OK
  • Net income$53.8M, +40.6%OK
  • Equity$448.3M, +21.1%OK
  • Debt$146.4M new long-term debtWatch
  • Insiders0 purchases / 2 salesWatch
  • AccountingForensic screens unavailableNote

Business

Bowhead Specialty offers commercial specialty property and casualty insurance focused on casualty, professional liability, healthcare liability, and Baleen Specialty lines.

Leadership changes

From Bowhead Specialty Holdings Inc.'s own filings, the day they're filed.

  • Ava Schnidman · departureeff. 2025-10-02
  • David Holman · departureeff. 2025-10-02
  • Ava Schnidman · director · departureeff. 2024-10-30

Latest filings

  • 8-K · Company announcement2026-08-19
  • DEF 14A · Annual proxy (pay & governance)2026-08-05
  • DEF 14A · Annual proxy (pay & governance)2026-08-03
  • 10-Q · Quarterly report2026-08-03
  • 8-K · Company announcement2026-08-03
In the full recordFree for 14 days
  • What changed🔒
  • Insider signal🔒
  • Growth quality🔒
  • Margins & accounting🔒
  • Capital allocation🔒
  • Real risks🔒
  • The long arc🔒
  • Company history🔒
  • Main tension🔒
  • The filings, readable — with what changed vs the prior year highlighted🔒
  • Full financial statements, industry-aware, sources cited throughout🔒
  • Forensic score history & components — the trend, not one year🔒
  • Ownership: insider buys/sells, clusters, activist stakes🔒
  • Ana — ask about Bowhead Specialty Holdings Inc., every answer cited to the official filings🔒

Every figure comes from the company's filings, and analysis whose figures don't match SEC data is rejected before publication.

14-day free trial, no credit card. For research purposes only; not investment advice.